Section Arrow
ONC.NASDAQ
- BeOne Medicines Ltd
Quotes are at least 15-min delayed:2025/09/05 13:58 EDT
Regular Hours
Last
 338.18
+19.45 (+6.10%)
Day High 
341.99 
Prev. Close
318.73 
1-M High
339.86 
Volume 
212.83K 
Bid
337.46
Ask
338.84
Day Low
335.75 
Open
338.49 
1-M Low
280.11 
Market Cap 
35.07B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 313.64 
20-SMA 309.02 
50-SMA 288.63 
52-W High 339.86 
52-W Low 170.99 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.69/7.13
Enterprise Value
35.28B
Balance Sheet
Book Value Per Share
34.27
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
238.39M
Operating Revenue Per Share
17.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.04855-0.00245-4.80%-- 
NUVBNuvation Bio3.92+0.5+14.62%-- 
IOVAIovance Biotherapeutics2.4+0.2+9.09%-- 
RXRXRecursion Pharmaceuticals4.5774+0.0574+1.27%-- 
MRNAModerna25.185+0.905+3.73%-- 
Quotes are at least 15-min delayed:2025/09/05 13:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.